Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Authors:
- J M RiberaJRJ M Ribera
- ESMO Guidelines CommitteeECESMO Guidelines Committee
Top Cited Papers
Open Access
- 7 April 2016
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_5) , v69-v82
Abstract
The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related variations (0.53 at 45–54 years, ∼1.0 at 55–74 years and 1.45 at 75–99 years) and that of Burkitt leukaemia/lymphoma is between 0.17 and 0.33 in the same age groups [1]. These figures qualify ALL as a rare disease in adults, making assessment and care at qualified centres highly desirable. Predisposing risk factors for adult ALL are not known, contrary to childhood ALL [2]. Therapeutic progress is undeniable as shown by large registry data. In Europe, 5-year overall survival (OS) improved from 29.8% in the years 1997–1999 to 41.1% in 2006–2008 (P < 0.0001), still as a function of age. Compared with the reference group (age 15–54 years: OS >50%), OS was <30% in the 55–64 years age group (hazard ratio 2.05) and <20% in the ≥65 years age group (hazard ratios 2.71 and 3.75) [3].Keywords
This publication has 96 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesLeukemia, 2012
- Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE projectBlood, 2010
- Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2010
- Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia GroupHaematologica, 2010
- T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)Blood, 2009
- Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009Bone Marrow Transplantation, 2009
- Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemiaThe Lancet Oncology, 2009
- Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 studyBlood, 2008
- Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Blood, 2007